China–U.S. Health Dialogue Delegation Visits Sinocare

On April 24, a delegation of nearly 100 participants from the 2026 China–U.S. Young Leaders Dialogue on Health (Changsha Session) visited Sinocare Inc. for an exchange on innovation in chronic disease management and international collaboration.

The delegation, composed of young physicians and medical students from China and the United States, engaged with Sinocare’s leadership and technical teams on topics including digital health, AI applications, and global cooperation in chronic disease care.

As a key corporate visit of the Changsha program, the event was hosted by Sinocare’s senior management, including Ms. Li Xinyi, Vice Chairman and General Manager; Dr. Cai Xiaohua, Chief Scientist; Dr. Fei Jiangfeng, Director of Strategy and Business Development; Ms. Wang Jingman (Karman), International Marketing Manager; and Mr. Tang Yang, Manager of the CGM Global Customer Service Center.

During the visit, the delegation toured Sinocare’s exhibition center to learn about the company’s development, core technologies, and global footprint. The group also visited the Sinocare Diabetes Clinic, where they observed integrated care models combining in-clinic services with digital health management.

A key highlight of the visit was Sinocare’s non-invasive diabetes risk screening technology, which uses ocular fluorescence scanning to assess future diabetes risk within seconds. Delegates experienced the technology on site and discussed its potential applications in early screening, particularly in primary care and high-risk population management.

Following the tour, participants joined a focused discussion session.

In her opening remarks, Ms. Li Xinyi highlighted Sinocare’s ongoing engagement with international academic and clinical communities. Collaborative programs, including joint training initiatives with leading universities, have supported bilateral exchange and contributed to the development of globally oriented medical talent.

Ms. Wang Jingman presented Sinocare’s international strategy, outlining its presence in global diabetes monitoring markets, recent technological developments, and long-term growth priorities.

Mr. Tang Yang introduced Sinocare’s AI-enabled approach to chronic disease management, covering applications such as intelligent glucose monitoring, risk prediction, and personalized patient support. These solutions aim to improve care efficiency and enhance patient outcomes across different healthcare settings.

During the discussion, participants exchanged views on the clinical adoption of new technologies, global public health collaboration, and the role of young professionals in advancing healthcare innovation.

The visit formed an important part of the 2026 China–U.S. Young Leaders Dialogue on Health (Changsha Session), providing an opportunity for participants to explore China’s evolving landscape in chronic disease management and digital health.

Looking ahead, Sinocare will continue to strengthen international collaboration and advance innovation in diabetes monitoring and management, contributing to improved global health outcomes.